Literature DB >> 8786536

Methcathinone: an initial study of its effects on monoaminergic systems.

M P Gygi1, J W Gibb, G R Hanson.   

Abstract

Methcathinone is a stimulant recently designated a Schedule I drug. Its use and popularity are growing; however, little data are available concerning its neurochemical properties. We investigated the effects of single and multiple doses of methcathinone on dopaminergic and serotonergic systems in the rat. Multiple doses of 30 mg/kg methcathinone caused dramatic decreases in neurochemical parameters associated with both dopaminergic and serotonergic systems in the striatum; corresponding decreases also occurred in serotonergic parameters in hippocampus and frontal cortex. These reductions in enzyme activity and concentrations of transmitters and their metabolites were apparent of 18 and 72 hr after drug administration. In addition, a single dose of methcathinone caused a significant decrease in the serotonergic enzyme activity in the striatum that was evident at 30 min and 2 hr after drug administration. We found that doses of 10 and 20 mg/kg causes no effect on striatal monoaminergic systems; however, doses higher that the 30 mg/kg dose caused significant lethality. In comparison with other stimulants of abuse, methcathinone appears to be most similar to methamphetamine with regard to its effects on monamine systems.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8786536

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum.

Authors:  Mariana Angoa-Pérez; Michael J Kane; Dina M Francescutti; Katherine E Sykes; Mrudang M Shah; Abiy M Mohammed; David M Thomas; Donald M Kuhn
Journal:  J Neurochem       Date:  2012-02-09       Impact factor: 5.372

2.  Dissecting the Influence of Two Structural Substituents on the Differential Neurotoxic Effects of Acute Methamphetamine and Mephedrone Treatment on Dopamine Nerve Endings with the Use of 4-Methylmethamphetamine and Methcathinone.

Authors:  John H Anneken; Mariana Angoa-Pérez; Girish C Sati; David Crich; Donald M Kuhn
Journal:  J Pharmacol Exp Ther       Date:  2016-12-30       Impact factor: 4.030

Review 3.  Neurotoxicology of Synthetic Cathinone Analogs.

Authors:  Mariana Angoa-Pérez; John H Anneken; Donald M Kuhn
Journal:  Curr Top Behav Neurosci       Date:  2017

4.  Assessing the role of dopamine in the differential neurotoxicity patterns of methamphetamine, mephedrone, methcathinone and 4-methylmethamphetamine.

Authors:  John H Anneken; Mariana Angoa-Perez; Girish C Sati; David Crich; Donald M Kuhn
Journal:  Neuropharmacology       Date:  2017-08-26       Impact factor: 5.250

5.  Differential effects of cathinone compounds and MDMA on body temperature in the rat, and pharmacological characterization of mephedrone-induced hypothermia.

Authors:  S E Shortall; A R Green; K M Swift; K C F Fone; M V King
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

6.  Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA.

Authors:  Mariana Angoa-Pérez; Michael J Kane; Denise I Briggs; Dina M Francescutti; Catherine E Sykes; Mrudang M Shah; David M Thomas; Donald M Kuhn
Journal:  J Neurochem       Date:  2013-01-08       Impact factor: 5.372

7.  Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428.

Authors:  U D McCann; D F Wong; F Yokoi; V Villemagne; R F Dannals; G A Ricaurte
Journal:  J Neurosci       Date:  1998-10-15       Impact factor: 6.167

Review 8.  Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues.

Authors:  Fabrizio Schifano; Antonio Albanese; Suzanne Fergus; Jackie L Stair; Paolo Deluca; Ornella Corazza; Zoe Davey; John Corkery; Holger Siemann; Norbert Scherbaum; Magi' Farre'; Marta Torrens; Zsolt Demetrovics; A Hamid Ghodse
Journal:  Psychopharmacology (Berl)       Date:  2010-11-12       Impact factor: 4.530

Review 9.  Psychostimulants and movement disorders.

Authors:  Andres Asser; Pille Taba
Journal:  Front Neurol       Date:  2015-04-20       Impact factor: 4.003

10.  Grey matter abnormalities in methcathinone abusers with a Parkinsonian syndrome.

Authors:  Julius Juurmaa; Ricarda A L Menke; Pierre Vila; Andreas Müürsepp; Tiiu Tomberg; Pilvi Ilves; Mait Nigul; Heidi Johansen-Berg; Michael Donaghy; Charlotte J Stagg; Ainārs Stepens; Pille Taba
Journal:  Brain Behav       Date:  2016-08-18       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.